Insider Trading Tracker: Live US Stock Disclosures & Insider Buying made on Aug 12, 2024

Advanced/Help

"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches "Balanced Fund" but not "Balanced Growth Fund" Balanced Fund: Use this format without quotation marks to search for all funds related to the term "Balanced Fund" The results may include "Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".

Showing you 400 results sorted by most recent dates. Subscribe to see a larger data set

Stock	Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Citius Oncology Inc	Leonard L. Mazur	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	3,700,000	3,700,000	-		-	Stock Option (Right to Buy)
Elicio Therapeutics Inc	Yekaterina Chudnovsky	Director, Ten Percent Owner	Purchase of securities on an exchange or from another person at price $ 0.00 per share.	12 Aug 2024	3,442,341	3,442,341	-		-	Convertible Note (convertible into Common Stock)
Energy Transfer LP - Unit	Kelcy L. Warren	Director	Purchase of securities on an exchange or from another person at price $ 15.68 per share.	12 Aug 2024	3,000,000	123,385,650 (4%)	0%	15.7	47,040,000	Common Units
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	2,094,650	2,094,650	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	2,094,650	0	-		-	Series B-4 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	2,094,650	2,094,650	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	2,094,650	0	-		-	Series B-4 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	2,022,029	2,022,029	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	2,022,029	0	-		-	Series B-4 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	2,022,029	2,022,029	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	2,022,029	0	-		-	Series B-4 Redeemable Convertible Preferred Stock
Renovaro Biosciences Inc	Karen Brink	Director, Ten Percent Owner	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	2,000,000	23,372,969 (50%)	4%		-	Common Stock
Renovaro Biosciences Inc	Karen Brink	Director, Ten Percent Owner	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	2,000,000	25,372,969 (54%)	4%		-	Common Stock
System1 Inc (Class A) Board Meeting	Michael Blend	Director, CEO & Chairman	Gift of securities by or to the insider at price $ 0.00 per share.	12 Aug 2024	1,850,215	0	-		0	Class A Common Stock
System1 Inc (Class A) Board Meeting	Michael Blend	Director, CEO & Chairman	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	1,850,215	1,850,215	-		0	Class A Common Stock
Citius Oncology Inc	Myron Z. Holubiak	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	1,500,000	1,500,000	-		-	Stock Option (Right to Buy)
Citius Oncology Inc	Jaime Bartushak	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	1,400,000	1,400,000	-		-	Stock Option (Right to Buy)
Citius Oncology Inc	Myron Czuczman	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	1,400,000	1,400,000	-		-	Stock Option (Right to Buy)
Citius Oncology Inc	Leonard L. Mazur	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	1,233,333	1,233,333	-		-	Stock Option (Right to Buy)
CuriosityStream Inc - Ordinary Shares- Class A	Clinton Larry Stinchcomb	Director, President and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	1,062,500	1,062,500	-		-	Restricted Stock Units
CuriosityStream Inc - Ordinary Shares- Class A	Clinton Larry Stinchcomb	Director, President and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	1,062,500	2,053,951	-		-	Common Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	1,058,318	1,105,636	-		-	Common Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	1,058,318	0	-		-	Series B-1 Redeemable Convertible Preferred Stock
Compass Inc (Class A)	Robert Reffkin	Director, Chairman and CEO	Sale of securities on an exchange or to another person at price $ 4.22 per share.	12 Aug 2024	972,336	0	-	4.2	4,101,410	Class A Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	884,427	884,427	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	884,427	0	-		-	Convertible Note
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	884,427	884,427	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	884,427	0	-		-	Convertible Note
Unilever PLC (ADR)	Nelson Peltz	Non-Executive Director	Sale of securities on an exchange or to another person at price $ 47.19 per share.	12 Aug 2024	738,471	32,949,772 (1%)	0%	47.2	34,848,446	Ords
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	726,163	726,163	-		-	Common Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	726,163	0	-		-	Series B-2 Redeemable Convertible Preferred Stock
Figs Inc (Class A)	Sarah Oughtred	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	656,815	656,815	-		0	Class A Common Stock
Compass Inc (Class A)	Robert Reffkin	Director, Chairman and CEO	Sale or transfer of securities back to the company at price $ 0.00 per share.	12 Aug 2024	578,850	14,633,787	-		-	Class C Common Stock
Compass Inc (Class A)	Robert Reffkin	Director, Chairman and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	578,850	972,336	-		0	Class A Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	573,394	573,394	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	573,394	0	-		-	Series C Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	573,394	573,394	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	573,394	0	-		-	Series C Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	525,797	525,797	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	525,797	0	-		-	Series A Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	525,797	525,797	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	525,797	0	-		-	Series A Redeemable Convertible Preferred Stock
Compass Inc (Class A)	Robert Reffkin	Director, Chairman and CEO	Sale of securities on an exchange or to another person at price $ 4.16 per share.	12 Aug 2024	500,000	7,828,116	-	4.2	2,081,100	Class A Common Stock
Citius Oncology Inc	Myron Z. Holubiak	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	500,000	500,000	-		-	Stock Option (Right to Buy)
FTC Solar Inc High Loss High Volume	Isidoro Quiroga Cortes	Former Director	Purchase of securities on an exchange or from another person at price $ 0.22 per share.	12 Aug 2024	500,000	1,580,403	-	0.2	110,000	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	484,638	2,506,667	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	484,638	0	-		-	Series C Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	484,638	2,506,667	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	484,638	0	-		-	Series C Redeemable Convertible Preferred Stock
Citius Oncology Inc	Jaime Bartushak	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	466,667	466,667	-		-	Stock Option (Right to Buy)
Citius Oncology Inc	Myron Czuczman	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	466,667	466,667	-		-	Stock Option (Right to Buy)
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	462,073	462,073	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	462,073	0	-		-	Series B-1 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	462,073	462,073	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	462,073	0	-		-	Series B-1 Redeemable Convertible Preferred Stock
Edgewise Therapeutics Inc	Kevin Koch	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	431,250	431,250	-		-	Stock Option (Right to Buy)
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner	Purchase of securities on an exchange or from another person at price $ 8.00 per share.	12 Aug 2024	375,000	1,259,427	-	8	3,000,000	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner	Purchase of securities on an exchange or from another person at price $ 8.00 per share.	12 Aug 2024	375,000	1,259,427	-	8	3,000,000	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	332,867	971,439	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	332,867	0	-		-	Series B-3 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	332,867	971,439	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	332,867	0	-		-	Series B-3 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	326,547	326,547	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	326,547	0	-		-	Series B-4 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	326,547	0	-		-	Series B-4 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	326,547	326,547	-		-	Common Stock
Acadia Pharma Inc	Elizabeth H.Z. Thompson	EVP, Head of Research & Dev	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	324,582	324,582	-		-	Stock Option (Right to Buy)
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	309,589	309,589	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	309,589	0	-		-	Series B-4 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	309,589	309,589	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	309,589	0	-		-	Series B-4 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	307,538	307,538	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	307,538	0	-		-	Series A Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	307,538	307,538	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	307,538	0	-		-	Series A Redeemable Convertible Preferred Stock
BeiGene Ltd (ADR)	Xiaodong Wang	Director, Chair, Scientific Advisory Brd	Gift of securities by or to the insider at price $ 0.00 per share.	12 Aug 2024	301,457	5,266,973 (0%)	0%		0	Ordinary Shares
CuriosityStream Inc - Ordinary Shares- Class A	Tia Cudahy	COO, Gen Counsel and Secretary	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	267,375	435,470	-		-	Common Stock
CuriosityStream Inc - Ordinary Shares- Class A	Tia Cudahy	COO, Gen Counsel and Secretary	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	267,375	267,375	-		-	Restricted Stock Units
Fox Corp (Class A)	Lachlan K. Murdoch	Director, Executive Chair, CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	235,646	235,646	-		-	Performance Stock Option (Right to Buy)
Unicycive Therapeutics Inc	Shalabh K. Gupta	Director, CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	232,868	6,439,505	-		-	Stock Options
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	230,597	230,597	-		-	Common Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	230,597	0	-		-	Series B-4 Redeemable Convertible Preferred Stock
FTC Solar Inc High Loss High Volume	Ahmad R. Chatila	Director	Purchase of securities on an exchange or from another person at price $ 0.23 per share.	12 Aug 2024	212,800	1,403,046	-	0.2	48,944	Common Stock
Telos Corp	Fredrick D. Schaufeld	Director	Purchase of securities on an exchange or from another person at price $ 2.51 per share.	12 Aug 2024	212,463	1,556,610	-	2.5	533,282	Common Stock
Lexicon Pharma Inc	Brian Corrigan	SVP, Regulatory & QA		12 Aug 2024	200,000	200,000	-		-	Stock Option (Right to Buy)
The Baldwin Insurance Grp Inc (Class A)	James Roche	See Remarks		12 Aug 2024	200,000	1,036,786	-		-	LLC Units in The Baldwin Insurance Group Holdings, LLC
The Baldwin Insurance Grp Inc (Class A)	James Roche	See Remarks		12 Aug 2024	200,000	445,817 (2%)	1%		0	Class A Common Stock
The Baldwin Insurance Grp Inc (Class A)	James Roche	See Remarks		12 Aug 2024	200,000	1,036,786	-		0	Class B Common Stock
QuantumScape Corp (Class A) Results Board Meeting 10-year low	Jagdeep Singh	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.31 per share.	12 Aug 2024	192,270	3,001,523	-	1.3	252,412	Class A Common Stock
QuantumScape Corp (Class A) Results Board Meeting 10-year low	Jagdeep Singh	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	192,270	1,730,430	-		-	Stock Option (right to buy)
QuantumScape Corp (Class A) Results Board Meeting 10-year low	Jagdeep Singh	Director	Sale of securities on an exchange or to another person at price $ 5.50 per share.	12 Aug 2024	192,270	2,809,253	-	5.5	1,057,927	Class A Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	176,499	638,572	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	176,499	0	-		-	Series B-2 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	176,499	638,572	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	176,499	0	-		-	Series B-2 Redeemable Convertible Preferred Stock
Lemonade Inc	Daniel Schreiber	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	167,130	167,130	-		-	STOCK OPTION
Lemonade Inc	Shai Wininger	Director, President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	167,130	167,130	-		-	STOCK OPTION
Elutia Inc (Class A)	C. Randal Mills	Director, PRESIDENT AND CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	162,500	0	-		-	Restricted Stock Units
Elutia Inc (Class A)	C. Randal Mills	Director, PRESIDENT AND CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	162,500	292,467	-		-	Class A Common Stock
Fox Corp (Class A)	Lachlan K. Murdoch	Director, Executive Chair, CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	161,384	161,384	-		-	Restricted Stock Units
Telos Corp	John B. Wood	Director, Chairman and CEO	Purchase of securities on an exchange or from another person at price $ 2.39 per share.	12 Aug 2024	158,644	5,026,925	-	2.4	379,159	Common Stock
OppFi Inc (Class A)	Todd G. Schwartz	Director, Chief Executive Officer, Ten Percent Owner	Sale or transfer of securities back to the company at price $ 0.00 per share.	12 Aug 2024	154,655	65,847,018	-		0	Class V Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	153,702	153,702	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	153,702	0	-		-	Series B-1 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	153,702	153,702	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	153,702	0	-		-	Series B-1 Redeemable Convertible Preferred Stock
N-able Inc	John Pagliuca	Director, President and CEO	Sale of securities on an exchange or to another person at price $ 12.77 per share.	12 Aug 2024	150,956	1,465,346	-	12.8	1,927,708	Common Stock, par value $0.001 per share
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	150,240	1,659,237	-		-	Class B Common Stock
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	150,240	1,502,400	-		-	Stock Option (Right to Buy)
Citius Oncology Inc	Dennis M. McGrath	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	150,000	150,000	-		-	Stock Option (Right to Buy)
Citius Oncology Inc	Suren G. Dutia	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	150,000	150,000	-		-	Stock Option (Right to Buy)
Citius Oncology Inc	Carol Webb	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	150,000	150,000	-		-	Stock Option (Right to Buy)
Citius Oncology Inc	Eugene Holuka	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	150,000	150,000	-		-	Stock Option (Right to Buy)
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	147,047	300,749	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	147,047	0	-		-	Series B-2 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	147,047	300,749	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	147,047	0	-		-	Series B-2 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	146,870	873,033	-		-	Common Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	146,870	0	-		-	Series B-3 Redeemable Convertible Preferred Stock
Claros Mortgage Trust Inc	Richard Mack	Director, CEO AND CHAIRMAN	Sale or transfer of securities back to the company at price $ 8.41 per share.	12 Aug 2024	141,872	2,449,981	-	8.4	1,193,144	COMMON STOCK
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	141,457	141,457	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	141,457	0	-		-	Series B-1 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	141,457	141,457	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	141,457	0	-		-	Series B-1 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	138,889	138,889	-		-	Common Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	138,889	0	-		-	Series B-3 Redeemable Convertible Preferred Stock
Edgewise Therapeutics Inc	John R. Moore	General Counsel	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	138,750	138,750	-		-	Stock Option (Right to Buy)
Edgewise Therapeutics Inc	R. Michael Carruthers	Chief Financial Officer		12 Aug 2024	138,750	138,750	-		-	Stock Option (Right to Buy)
Edgewise Therapeutics Inc	Joanne M. Donovan	CMO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	138,750	138,750	-		-	Stock Option (Right to Buy)
Edgewise Therapeutics Inc	Marc Semigran	Chief Development Officer		12 Aug 2024	138,750	138,750	-		-	Stock Option (Right to Buy)
Edgewise Therapeutics Inc	Alan Russell	Director, Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	138,750	138,750	-		-	Stock Option (Right to Buy)
Edgewise Therapeutics Inc	Behrad Derakhshan	Chief Business Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	138,750	138,750	-		-	Stock Option (Right to Buy)
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	132,908	0	-		-	Series B-4 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	132,908	271,797	-		-	Common Stock
Klaviyo Inc - Ordinary Shares - Series A	Allen Chaves	Chief Technology Officer		12 Aug 2024	130,000	130,000	-		0	Series A Common Stock
Klaviyo Inc - Ordinary Shares - Series A	Allen Chaves	Chief Technology Officer		12 Aug 2024	130,000	206,742	-		-	Series B Common Stock
Klaviyo Inc - Ordinary Shares - Series A	Allen Chaves	Chief Technology Officer		12 Aug 2024	130,000	336,742	-		-	Series B Common Stock
Klaviyo Inc - Ordinary Shares - Series A	Allen Chaves	Chief Technology Officer		12 Aug 2024	130,000	1,191,426	-		-	Stock Option (Right to Buy)
SAB Biotherapeutics Inc	Lucy To	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	125,000	125,000	-		-	Employee Stock Option (right to buy)
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner	Purchase of securities on an exchange or from another person at price $ 8.00 per share.	12 Aug 2024	125,000	125,000	-	8	1,000,000	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner	Purchase of securities on an exchange or from another person at price $ 8.00 per share.	12 Aug 2024	125,000	125,000	-	8	1,000,000	Common Stock
Klaviyo Inc - Ordinary Shares - Series A	Allen Chaves	Chief Technology Officer		12 Aug 2024	119,491	10,509	-	31.6	3,779,500	Series A Common Stock
Palantir	David Glazer	See Remarks	Sale of securities on an exchange or to another person at price $ 31.18 per share.	12 Aug 2024	107,500	298,012	-	31.2	3,351,893	Class A Common Stock
Palantir	David Glazer	See Remarks	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	107,500	495,156	-		-	Employee Stock Option (Right to buy)
Palantir	David Glazer	See Remarks	Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.72 per share.	12 Aug 2024	107,500	405,512	-	4.7	507,400	Class A Common Stock
Fox Corp (Class A)	John P. Nallen	Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	107,112	107,112	-		-	Performance Stock Option (Right to Buy)
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	101,900	297,389	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	101,900	0	-		-	Series B-3 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	101,900	297,389	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	101,900	0	-		-	Series B-3 Redeemable Convertible Preferred Stock
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer	Sale of securities on an exchange or to another person at price $ 111.67 per share.	12 Aug 2024	101,479	359,648 (0%)	0%	111.7	11,331,713	Class A Common Stock
Elanco Animal Health Inc	Jeffrey N. Simmons	Director, PRESIDENT, CEO AND DIRECTOR	Purchase of securities on an exchange or from another person at price $ 13.01 per share.	12 Aug 2024	100,000	145,000 (0%)	0%	13.0	1,300,610	Common Stock
The Baldwin Insurance Grp Inc (Class A)	Lowry Baldwin	Director, Ten Percent Owner, See Remarks	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	100,000	13,049,090	-		0	Class B Common Stock
The Baldwin Insurance Grp Inc (Class A)	Lowry Baldwin	Director, Ten Percent Owner, See Remarks		12 Aug 2024	100,000	0	-		-	LLC Units in The Baldwin Insurance Group Holdings, LLC
The Baldwin Insurance Grp Inc (Class A)	Lowry Baldwin	Director, Ten Percent Owner, See Remarks	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	100,000	100,000	-		-	LLC Units in The Baldwin Insurance Group Holdings, LLC
The Baldwin Insurance Grp Inc (Class A)	Lowry Baldwin	Director, Ten Percent Owner, See Remarks	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	100,000	13,049,090	-		-	LLC Units in The Baldwin Insurance Group Holdings, LLC
The Baldwin Insurance Grp Inc (Class A)	Lowry Baldwin	Director, Ten Percent Owner, See Remarks		12 Aug 2024	100,000	100,000 (0%)	0%		0	Class A Common Stock
The Baldwin Insurance Grp Inc (Class A)	Lowry Baldwin	Director, Ten Percent Owner, See Remarks		12 Aug 2024	100,000	0	-		0	Class B Common Stock
The Baldwin Insurance Grp Inc (Class A)	Lowry Baldwin	Director, Ten Percent Owner, See Remarks	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	100,000	100,000	-		0	Class B Common Stock
Vital Farms Inc	Russell Diez-Canseco	Director, PRESIDENT AND CEO	Sale of securities on an exchange or to another person at price $ 30.71 per share.	12 Aug 2024	100,000	515,404	-	30.7	3,071,000	Common Stock
Teva- pharma Ind Ltd (ADR)	Richard Daniell	Exec. VP, European Commercial	Sale of securities on an exchange or to another person at price $ 17.30 per share.	12 Aug 2024	98,943	0 (0%)	0%	17.3	1,711,447	Ordinary Shares
Vital Farms Inc	Russell Diez-Canseco	Director, PRESIDENT AND CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.33 per share.	12 Aug 2024	94,758	610,162	-	5.3	504,927	Common Stock
Vital Farms Inc	Russell Diez-Canseco	Director, PRESIDENT AND CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	94,758	543,764	-		-	Employee Stock Option (right to buy)
Roku Inc (Class A)	Anthony Wood	Director, CEO and Chairman BOD, Ten Percent Owner	Gift of securities by or to the insider at price $ 0.00 per share.	12 Aug 2024	94,247	94,247 (0%)	0%		0	Class A Common Stock
Dyne Therapeutics Inc	Dirk Kersten	Director	Sale of securities on an exchange or to another person at price $ 42.78 per share.	12 Aug 2024	88,179	1,675,117	-	42.8	3,772,298	Common Stock
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer		12 Aug 2024	85,637	433,321 (0%)	0%	0.3	26,265	Class A Common Stock
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer		12 Aug 2024	85,637	1,573,600	-		-	Class B Common Stock
The Baldwin Insurance Grp Inc (Class A)	James Roche	See Remarks	Sale of securities on an exchange or to another person at price $ 41.50 per share.	12 Aug 2024	85,222	254,681 (1%)	0%	41.5	3,536,713	Class A Common Stock
Roku Inc (Class A)	Anthony Wood	Director, CEO and Chairman BOD, Ten Percent Owner	Gift of securities by or to the insider at price $ 0.00 per share.	12 Aug 2024	84,207	0 (0%)	0%		0	Class A Common Stock
Liveperson Inc Board Meeting 10-year low	John Collins	CFO and COO	Sale of securities on an exchange or to another person at price $ 1.12 per share.	12 Aug 2024	83,735	372,730 (0%)	0%	1.1	93,783	Common Stock
Unicycive Therapeutics Inc	Pramod Gupta	EVP, Pharmaceuticals and BD	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	81,750	2,119,862	-		-	Stock Options
Unicycive Therapeutics Inc	Douglas Jermasek	EVP of Corporate Strategy	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	81,750	2,055,000	-		-	Stock Options
GoodRx Holdings Inc (Class A)	Romin Nabiey	Chief Accounting Officer		12 Aug 2024	79,000	64,633	-	6.8	534,625	Class A Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	78,267	404,814	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	78,267	0	-		-	Series C Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	78,267	404,814	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	78,267	0	-		-	Series C Redeemable Convertible Preferred Stock
Goodyear Tire & Rubber Co.	David Emmitt Phillips	Sr VP and General Counsel	Sale of securities on an exchange or to another person at price $ 7.89 per share.	12 Aug 2024	77,009	0 (0%)	0%	7.9	607,601	Common Stock
Tarsus Pharma Inc	William J. Link	Director	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	74,892	35,000	-		0	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	74,202	383,791	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	74,202	0	-		-	Series C Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	74,202	383,791	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	74,202	0	-		-	Series C Redeemable Convertible Preferred Stock
Fox Corp (Class A)	John P. Nallen	Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	73,356	73,356	-		-	Restricted Stock Units
Palantir	David Glazer	See Remarks	Sale of securities on an exchange or to another person at price $ 31.18 per share.	12 Aug 2024	72,500	298,012	-	31.2	2,260,550	Class A Common Stock
Palantir	David Glazer	See Remarks	Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.72 per share.	12 Aug 2024	72,500	370,512	-	4.7	342,200	Class A Common Stock
Palantir	David Glazer	See Remarks	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	72,500	422,656	-		-	Employee Stock Option (Right to buy)
Edgewise Therapeutics Inc	Kevin Koch	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	71,875	71,875	-		-	Restricted Stock Units
Aeva Tech Inc	Mina Rezk	Director, Chief Technology Officer, Ten Percent Owner	Sale of securities on an exchange or to another person at price $ 2.84 per share.	12 Aug 2024	70,000	8,836,669	-	2.8	198,842	Common Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	69,445	1,175,081	-		-	Common Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	69,445	0	-		-	Series B-3 Redeemable Convertible Preferred Stock
Insmed Inc	Michael A. Smith	Chief Legal Officer	Sale of securities on an exchange or to another person at price $ 72.75 per share.	12 Aug 2024	67,655	109,142 (0%)	0%	72.7	4,921,901	Common Stock
N-able Inc	Tim O’Brien	EVP, Chief Financial Officer	Sale of securities on an exchange or to another person at price $ 12.94 per share.	12 Aug 2024	66,862	587,370	-	12.9	865,194	Common Stock, par value $0.001 per share
Acadia Pharma Inc	Elizabeth H.Z. Thompson	EVP, Head of Research & Dev	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	64,544	64,544	-		-	Restricted Stock Units
Wave Life Sciences Ltd	Mark H.N. Corrigan	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	64,460	64,460	-		-	Share Option (right to buy)
Wave Life Sciences Ltd	Heidi L. Wagner	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	64,460	64,460	-		-	Share Option (right to buy)
Fox Corp (Class A)	Adam G. Ciongoli	Chief Legal and Policy Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	64,267	64,267	-		-	Performance Stock Options (Right to Buy)
Fox Corp (Class A)	Steven Tomsic	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	64,267	64,267	-		-	Performance Stock Options (Right to Buy)
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	61,857	61,857	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	61,857	0	-		-	Series B-1 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	61,857	61,857	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	61,857	0	-		-	Series B-1 Redeemable Convertible Preferred Stock
SentinelOne Inc (Class A)	Tomer Weingarten	Director, President, CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	60,864	4,453,517	-		-	Class B Common Stock
SentinelOne Inc (Class A)	Tomer Weingarten	Director, President, CEO	Sale of securities on an exchange or to another person at price $ 21.47 per share.	12 Aug 2024	60,864	1,099,356	-	21.5	1,306,671	Class A Common Stock
SentinelOne Inc (Class A)	Tomer Weingarten	Director, President, CEO		12 Aug 2024	60,864	1,160,220	-	9.7	592,815	Class A Common Stock
SentinelOne Inc (Class A)	Tomer Weingarten	Director, President, CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	60,864	4,877,922	-		-	Employee Stock Option (right to buy)
SentinelOne Inc (Class A)	Tomer Weingarten	Director, President, CEO		12 Aug 2024	60,864	4,392,653	-		-	Class B Common Stock
Elutia Inc (Class A)	C. Randal Mills	Director, PRESIDENT AND CEO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.84 per share.	12 Aug 2024	58,659	233,808	-	2.8	166,592	Class A Common Stock
QuantumScape Corp (Class A) Results Board Meeting 10-year low	Jagdeep Singh	Director	Sale of securities on an exchange or to another person at price $ 5.50 per share.	12 Aug 2024	57,690	5,831,618	-	5.5	317,428	Class A Common Stock
Applovin Corp (Class A)	Katie Jansen	Chief Marketing Officer	Sale of securities on an exchange or to another person at price $ 83.41 per share.	12 Aug 2024	54,793	1,109,603	-	83.4	4,570,284	Class A Common Stock
Roku Inc (Class A)	Anthony Wood	Director, CEO and Chairman BOD, Ten Percent Owner	Gift of securities by or to the insider at price $ 0.00 per share.	12 Aug 2024	54,702	0 (0%)	0%		0	Class A Common Stock
Roku Inc (Class A)	Anthony Wood	Director, CEO and Chairman BOD, Ten Percent Owner	Gift of securities by or to the insider at price $ 0.00 per share.	12 Aug 2024	54,702	84,207 (0%)	0%		0	Class A Common Stock
Spruce Power Holding Corp (Class A)	Kevin Griffin	Director		12 Aug 2024	54,662	54,662	-		0	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	54,032	195,489	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	54,032	0	-		-	Series B-2 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	54,032	195,489	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	54,032	0	-		-	Series B-2 Redeemable Convertible Preferred Stock
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	54,000	1,627,600	-		-	Class B Common Stock
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	54,000	756,000	-		-	Stock Option (Right to Buy)
Vital Farms Inc	Russell Diez-Canseco	Director, PRESIDENT AND CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	52,500	491,264	-		-	Employee Stock Option (right to buy)
Vital Farms Inc	Russell Diez-Canseco	Director, PRESIDENT AND CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.33 per share.	12 Aug 2024	52,500	567,904	-	5.3	279,752	Common Stock
Dyne Therapeutics Inc	Dirk Kersten	Director	Sale of securities on an exchange or to another person at price $ 43.42 per share.	12 Aug 2024	52,076	1,787,674	-	43.4	2,261,140	Common Stock
Allbirds Inc (Class A)	Timothy Brown	Director, Ten Percent Owner	Sale of securities on an exchange or to another person at price $ 0.59 per share.	12 Aug 2024	50,000	0	-	0.6	29,345	Class A Common Stock
Elutia Inc (Class A)	Matthew B. Ferguson	CHIEF FINANCIAL OFFICER	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	50,000	0	-		-	Restricted Stock Units
Elutia Inc (Class A)	Matthew B. Ferguson	CHIEF FINANCIAL OFFICER	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	50,000	307,823	-		-	Class A Common Stock
Elutia Inc (Class A)	Michelle Leroux Williams	CHIEF SCIENTIFIC OFFICER	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	50,000	67,100	-		-	Class A Common Stock
Elutia Inc (Class A)	Michelle Leroux Williams	CHIEF SCIENTIFIC OFFICER	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	50,000	0	-		-	Restricted Stock Units
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	49,984	0	-		-	Series C Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	49,984	321,781	-		-	Common Stock
Spruce Power Holding Corp (Class A)	Ja-Chin Audrey Lee	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	48,232	117,165	-		0	Common Stock
Spruce Power Holding Corp (Class A)	Clara Nagy McBane	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	48,232	120,987	-		0	Common Stock
Spruce Power Holding Corp (Class A)	Jonathan J. Ledecky	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	48,232	95,696	-		0	Common Stock
Spruce Power Holding Corp (Class A)	John P Miller	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	48,232	128,825	-		0	Common Stock
Fox Corp (Class A)	Lachlan K. Murdoch	Director, Executive Chair, CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	47,504	47,504	-		-	Performance Stock Units
Spire Global Inc (Class A)	Leonardo Basola	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	45,000	263,750	-		0	Class A Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	44,559	130,044	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	44,559	0	-		-	Series B-3 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	44,559	130,044	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	44,559	0	-		-	Series B-3 Redeemable Convertible Preferred Stock
Fox Corp (Class A)	Adam G. Ciongoli	Chief Legal and Policy Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	44,014	44,014	-		-	Restricted Stock Units
Fox Corp (Class A)	Steven Tomsic	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	44,014	44,014	-		-	Restricted Stock Units
DraftKings Inc (Class A)	Erik Bradbury	Chief Accounting Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	43,923	43,923	-		-	Restricted Stock Units
Applovin Corp (Class A)	Katie Jansen	Chief Marketing Officer	Sale of securities on an exchange or to another person at price $ 75.68 per share.	12 Aug 2024	42,340	1,180,004	-	75.7	3,204,291	Class A Common Stock
Live Oak Bancshares Inc Results Board Meeting	William C. Losch	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	42,000	113,625 (0%)	0%		-	Voting Common Stock
Live Oak Bancshares Inc Results Board Meeting	William C. Losch	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	42,000	84,000	-		-	Restricted Stock Units
Insmed Inc	Michael A. Smith	Chief Legal Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	41,640	0	-		-	Stock Option (right to buy)
Insmed Inc	Michael A. Smith	Chief Legal Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.91 per share.	12 Aug 2024	41,640	142,267 (0%)	0%	13.9	579,212	Common Stock
Beauty Health Co (Class A)	Brenton L. Saunders	Director, Chairman	Purchase of securities on an exchange or from another person at price $ 1.08 per share.	12 Aug 2024	40,450	5,921,769	-	1.1	43,686	Class A Common Stock
Unicycive Therapeutics Inc	John W. Townsend	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	40,256	915,565	-		-	Stock Options
Cardlytics Inc	Scott Anthony Hill	Director	Purchase of securities on an exchange or from another person at price $ 3.58 per share.	12 Aug 2024	40,000	40,000 (0%)	0%	3.6	143,200	Common Stock
FTC Solar Inc High Loss High Volume	Isidoro Quiroga Cortes	Former Director	Purchase of securities on an exchange or from another person at price $ 0.22 per share.	12 Aug 2024	40,000	1,620,403	-	0.2	8,800	Common Stock
Telos Corp	Fredrick D. Schaufeld	Director	Purchase of securities on an exchange or from another person at price $ 2.35 per share.	12 Aug 2024	37,537	1,594,147	-	2.4	88,212	Common Stock
Vital Farms Inc	Russell Diez-Canseco	Director, PRESIDENT AND CEO	Sale of securities on an exchange or to another person at price $ 30.34 per share.	12 Aug 2024	37,202	530,702	-	30.3	1,128,709	Common Stock
HNI Corp	Jeffrey D. Lorenger	Director, President & CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.03 per share.	12 Aug 2024	36,051	332,943 (0%)	0%	32.0	1,154,714	Common Stock
HNI Corp	Jeffrey D. Lorenger	Director, President & CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	36,051	36,051	-		-	Non-qualifying employee stock options (right to buy)
HNI Corp	Jeffrey D. Lorenger	Director, President & CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	36,051	0	-		-	Non-qualifying employee stock options (right to buy)
HNI Corp	Jeffrey D. Lorenger	Director, President & CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.03 per share.	12 Aug 2024	36,051	332,943 (0%)	0%	32.0	1,154,714	Common Stock
HNI Corp	Jeffrey D. Lorenger	Director, President & CEO	Sale of securities on an exchange or to another person at price $ 49.32 per share.	12 Aug 2024	35,951	296,992 (0%)	0%	49.3	1,773,103	Common Stock
HNI Corp	Jeffrey D. Lorenger	Director, President & CEO	Sale of securities on an exchange or to another person at price $ 49.32 per share.	12 Aug 2024	35,746	297,197 (0%)	0%	49.3	1,762,993	Common Stock
American Coastal Insurance Corp	Christopher Griffith	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	35,000	55,000	-		-	Nonqualified Stock Options
American Coastal Insurance Corp	Christopher Griffith	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 10.94 per share.	12 Aug 2024	35,000	134,656 (0%)	0%	10.9	382,981	Common Stock
American Coastal Insurance Corp	Christopher Griffith	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.46 per share.	12 Aug 2024	35,000	169,656 (0%)	0%	3.5	121,100	Common Stock
Geovax Labs Inc	David A. Dodd	Director, President, CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	35,000	35,000	-		-	Stock Option
CoreCivic Inc	David K. Churchill	Chief Human Resources		12 Aug 2024	35,000	229,056 (0%)	0%	12.6	441,700	Common Stock
Insmed Inc	Michael A. Smith	Chief Legal Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	34,530	34,530	-		-	Stock Option (right to buy)
Insmed Inc	Michael A. Smith	Chief Legal Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.07 per share.	12 Aug 2024	34,530	176,797 (0%)	0%	17.1	589,427	Common Stock
Liveperson Inc Board Meeting 10-year low	Monica L. Greenberg	EVP, Policy & General Counsel	Sale of securities on an exchange or to another person at price $ 1.12 per share.	12 Aug 2024	34,441	181,607 (0%)	0%	1.1	38,574	Common Stock
Klaviyo Inc - Ordinary Shares - Series A	Allen Chaves	Chief Technology Officer		12 Aug 2024	32,733	239,475	-		-	Series B Common Stock
Klaviyo Inc - Ordinary Shares - Series A	Allen Chaves	Chief Technology Officer		12 Aug 2024	32,733	1,158,693	-		-	Stock Option (Right to Buy)
Snap-on Results Board Meeting 10-year high	Nicholas T. Pinchuk	Director, Chairman, President and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 144.69 per share.	12 Aug 2024	32,500	783,164 (1%)	0%	144.7	4,702,425	Common Stock
Snap-on Results Board Meeting 10-year high	Nicholas T. Pinchuk	Director, Chairman, President and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	32,500	32,500	-		-	Stock Option (Right to Buy)
Wave Life Sciences Ltd	Christian O. Henry	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	32,230	32,230	-		-	Share Option (right to buy)
Wave Life Sciences Ltd	Mark H.N. Corrigan	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	32,230	32,230 (0%)	0%		0	Ordinary Shares
Wave Life Sciences Ltd	Adrian Rawcliffe	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	32,230	32,230	-		-	Share Option (right to buy)
Wave Life Sciences Ltd	Gregory L. Verdine	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	32,230	32,230	-		-	Share Option (right to buy)
Wave Life Sciences Ltd	Heidi L. Wagner	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	32,230	32,230 (0%)	0%		0	Ordinary Shares
Wave Life Sciences Ltd	Ken Takanashi	Director, Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	32,230	32,230	-		-	Share Option (right to buy)
Wave Life Sciences Ltd	Aik Na Tan	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	32,230	32,230	-		-	Share Option (right to buy)
Raymond James Financial Results Board Meeting	Tashtego S. Elwyn	CEO & President - RJA	Sale of securities on an exchange or to another person at price $ 109.64 per share.	12 Aug 2024	31,277	35,380 (0%)	0%	109.6	3,429,263	Common Stock
DXC Tech Co Board Meeting	Mary E. Finch	EVP, Chief People Officer		12 Aug 2024	31,047	325,665 (0%)	0%	19.4	600,915	Common Stock
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer		12 Aug 2024	30,780	1,596,820	-		-	Class B Common Stock
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer		12 Aug 2024	30,780	464,101 (0%)	0%	0.9	27,985	Class A Common Stock
Fox Corp (Class A)	Keith Rupert Murdoch	Chairman Emeritus		12 Aug 2024	30,230	30,230	-		-	Performance Stock Units
Actuate Therapeutics Inc	Amy L. Ronneberg	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	30,000	30,000	-		-	Non-Qualified Stock Options
Actuate Therapeutics Inc	Jason A. Keyes	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	30,000	30,000	-		-	Non-Qualified Stock Options
Actuate Therapeutics Inc	Roger Sawhney	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	30,000	30,000	-		-	Non-Qualified Stock Options
Tarsus Pharma Inc	William J. Link	Director	Sale of securities on an exchange or to another person at price $ 26.01 per share.	12 Aug 2024	29,979	5,021	-	26.0	779,754	Common Stock
Sezzle Inc Board Meeting	Paul M. Purcell	Former Director	Sale of securities on an exchange or to another person at price $ 121.61 per share.	12 Aug 2024	29,924	269,716	-	121.6	3,638,980	Common Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	28,464	0	-		-	Warrant (Right to Buy)
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	28,464	1,203,545	-	5.3	150,005	Common Stock
Compass Inc (Class A)	Robert Reffkin	Director, Chairman and CEO	Sale of securities on an exchange or to another person at price $ 4.17 per share.	12 Aug 2024	27,664	393,486	-	4.2	115,298	Class A Common Stock
Saratoga Investment Corp	Christian L. Oberbeck	Director, CEO and Director, Ten Percent Owner	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	27,256	642,825 (5%)	0%		0	Common Stock
Tarsus Pharma Inc	William J. Link	Director	Other type of transaction at price $ 0.00 per share.	12 Aug 2024	27,116	167,098	-		0	Common Stock
Dyne Therapeutics Inc	Dirk Kersten	Director	Sale of securities on an exchange or to another person at price $ 42.74 per share.	12 Aug 2024	26,416	1,839,750	-	42.7	1,129,020	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	26,355	997,794	-	5.3	138,891	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	26,355	0	-		-	Warrant (Right to Buy)
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	26,355	997,794	-	5.3	138,891	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	26,355	0	-		-	Warrant (Right to Buy)
Goodyear Tire & Rubber Co.	Laurette T. Koellner	Director	Purchase of securities on an exchange or from another person at price $ 7.90 per share.	12 Aug 2024	26,000	26,000 (0%)	0%	7.9	205,400	Common Stock
CuriosityStream Inc - Ordinary Shares- Class A	P. Brady Hayden	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	25,000	25,000	-		-	Restricted Stock Units
CuriosityStream Inc - Ordinary Shares- Class A	P. Brady Hayden	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	25,000	25,000	-		-	Common Stock
Live Oak Bancshares Inc Results Board Meeting	Renato Derraik	Chief Info./Digital Off., Bank	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	25,000	50,000	-		-	Restricted Stock Units
Live Oak Bancshares Inc Results Board Meeting	Renato Derraik	Chief Info./Digital Off., Bank	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	25,000	48,554 (0%)	0%		-	Voting Common Stock
Claros Mortgage Trust Inc	Priyanka Garg	SEE REMARKS	Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.41 per share.	12 Aug 2024	24,886	291,795	-	8.4	209,291	COMMON STOCK
Envista Holdings Corp	Eric D. Hammes	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 16.33 per share.	12 Aug 2024	24,532	24,532 (0%)	0%	16.3	400,608	Common Stock
Dyne Therapeutics Inc	Dirk Kersten	Director	Sale of securities on an exchange or to another person at price $ 42.08 per share.	12 Aug 2024	24,378	1,763,296	-	42.1	1,025,826	Common Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	24,138	0	-		-	Series C Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner		12 Aug 2024	24,138	254,735	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	23,628	85,485	-		-	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner		12 Aug 2024	23,628	0	-		-	Series B-2 Redeemable Convertible Preferred Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	23,628	85,485	-		-	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	23,628	0	-		-	Series B-2 Redeemable Convertible Preferred Stock
Claros Mortgage Trust Inc	J. Michael McGillis	Director, PRESIDENT AND CFO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.41 per share.	12 Aug 2024	23,589	451,830	-	8.4	198,383	COMMON STOCK
Puma biotech Inc	Michael P Miller	Director	Sale of securities on an exchange or to another person at price $ 3.49 per share.	12 Aug 2024	23,358	47,000 (0%)	0%	3.5	81,466	Common Stock
Edgewise Therapeutics Inc	John R. Moore	General Counsel	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	23,125	23,125	-		-	Restricted Stock Units
Edgewise Therapeutics Inc	R. Michael Carruthers	Chief Financial Officer		12 Aug 2024	23,125	23,125	-		-	Restricted Stock Units
Edgewise Therapeutics Inc	Joanne M. Donovan	CMO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	23,125	23,125	-		-	Restricted Stock Units
Edgewise Therapeutics Inc	Marc Semigran	Chief Development Officer		12 Aug 2024	23,125	23,125	-		-	Restricted Stock Units
Edgewise Therapeutics Inc	Alan Russell	Director, Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	23,125	23,125	-		-	Restricted Stock Units
Edgewise Therapeutics Inc	Behrad Derakhshan	Chief Business Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	23,125	23,125	-		-	Restricted Stock Units
TriplePoint Venture Growth BDC Corp	Sajal K. Srivastava	Director, President	Purchase of securities on an exchange or from another person at price $ 7.09 per share.	12 Aug 2024	22,759	273,617 (0%)	0%	7.1	161,286	Common Stock
Veracyte Inc	Evan Jones	Director	Sale of securities on an exchange or to another person at price $ 32.36 per share.	12 Aug 2024	22,407	6,085 (0%)	0%	32.4	725,026	Common Stock
Cigna Group	Nicole S. Jones	See Remarks	Sale of securities on an exchange or to another person at price $ 330.96 per share.	12 Aug 2024	22,030	24,587 (0%)	0%	331.0	7,291,049	Common Stock, $.01 Par Value
Fox Corp (Class A)	John P. Nallen	Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	21,592	21,592	-		-	Performance Stock Units
Dyne Therapeutics Inc	Dirk Kersten	Director	Sale of securities on an exchange or to another person at price $ 43.57 per share.	12 Aug 2024	21,428	1,653,689	-	43.6	933,618	Common Stock
Chemours Co	David A. Will	Chief Accounting Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	20,984	20,984 (0%)	0%		0	Common Stock
Exelixis Inc	Dana T. Aftab	CSO/EVP Disc & Trans Research	Sale of securities on an exchange or to another person at price $ 27.06 per share.	12 Aug 2024	20,883	500,107 (0%)	0%	27.1	565,094	Common Stock
Albany Intl Corp (Class A)	Christopher E. Stone	President AEC	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	20,714	20,714	-		-	Restricted Stock Units
Insmed Inc	Michael A. Smith	Chief Legal Officer	Sale of securities on an exchange or to another person at price $ 73.65 per share.	12 Aug 2024	20,415	88,727 (0%)	0%	73.7	1,503,565	Common Stock
Rigetti Computing Inc	Alissa M. Fitzgerald	Director	Sale of securities on an exchange or to another person at price $ 0.82 per share.	12 Aug 2024	20,000	173,667	-	0.8	16,400	Common Stock
Energy Transfer LP - Unit	Thomas E. Long	Director, Co-CEO	Purchase of securities on an exchange or from another person at price $ 15.68 per share.	12 Aug 2024	20,000	4,308,859 (0%)	0%	15.7	313,600	Common Units
Microvision Inc	Drew G. Markham	GC	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	20,000	0	-		-	Restricted Stock Units
Microvision Inc	Drew G. Markham	GC	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	20,000	193,691 (0%)	0%		0	Common Stock
Targa Resources 10-year high	D. Scott Pryor	See Remarks	Sale of securities on an exchange or to another person at price $ 137.66 per share.	12 Aug 2024	20,000	116,098 (0%)	0%	137.7	2,753,180	Common Stock
The Baldwin Insurance Grp Inc (Class A)	Lowry Baldwin	Director, Ten Percent Owner, See Remarks	Sale of securities on an exchange or to another person at price $ 41.36 per share.	12 Aug 2024	20,000	80,000 (0%)	0%	41.4	827,200	Class A Common Stock
Cloudflare Inc (Class A)	Douglas Kramer	CHIEF LEGAL OFFICER		12 Aug 2024	20,000	70,675	-		-	Class B Common Stock
Cloudflare Inc (Class A)	Douglas Kramer	CHIEF LEGAL OFFICER		12 Aug 2024	20,000	215,303 (0%)	0%		-	Class A Common Stock
Cloudflare Inc (Class A)	Douglas Kramer	CHIEF LEGAL OFFICER		12 Aug 2024	20,000	195,303 (0%)	0%		0	Class A Common Stock
Palantir	Heather Planishek	See Remarks		12 Aug 2024	20,000	30,000	-		-	Employee Stock Option (Right to buy)
Palantir	Heather Planishek	See Remarks		12 Aug 2024	20,000	612,006	-	30.2	604,856	Class A Common Stock
Palantir	Heather Planishek	See Remarks		12 Aug 2024	20,000	632,006	-	4.7	94,400	Class A Common Stock
T-Mobile US Results Board Meeting	G. Michael Sievert	Director, President and CEO	Sale of securities on an exchange or to another person at price $ 194.57 per share.	12 Aug 2024	20,000	418,124 (0%)	0%	194.6	3,891,400	Common Stock
T-Mobile US Results Board Meeting	G. Michael Sievert	Director, President and CEO	Sale of securities on an exchange or to another person at price $ 195.06 per share.	12 Aug 2024	20,000	398,124 (0%)	0%	195.1	3,901,200	Common Stock
ACM Research Inc (Class A)	Chenming C. Hu	Director		12 Aug 2024	20,000	20,000	-		-	Stock Option
ACM Research Inc (Class A)	Haiping Dun	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	20,000	20,000	-		-	Stock Option
ACM Research Inc (Class A)	Tracy Liu	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	20,000	20,000	-		-	Stock Option
Netflix Estimates Miss High Loss High Volume	Jay C. Hoag	Director	Sale of securities on an exchange or to another person at price $ 632.28 per share.	12 Aug 2024	19,086	330,433 (0%)	0%	632.3	12,067,675	Common Stock
a.k.a. Brands Holding Corp	Ciaran Long	Interim CEO and CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	18,750	71,517	-		0	Common Stock, $0.001 par value per share
a.k.a. Brands Holding Corp	Michael Trembley	See remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	18,750	47,116	-		0	Common Stock, $0.001 par value per share
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	18,750	1,615,570	-		-	Class B Common Stock
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	18,750	712,500	-		-	Stock Option (Right to Buy)
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner	Sale of securities on an exchange or to another person at price $ 8.00 per share.	12 Aug 2024	18,750	1,184,795	-	8	150,000	Common Stock
Live Oak Bancshares Inc Results Board Meeting	William C. Losch	Chief Financial Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.43 per share.	12 Aug 2024	18,665	94,960 (0%)	0%	38.4	717,296	Voting Common Stock
New York Times Co. (Class A)	Meredith Kopit Levien	Director, PRESIDENT & CEO	Sale of securities on an exchange or to another person at price $ 53.92 per share.	12 Aug 2024	18,300	101,772 (0%)	0%	53.9	986,773	Class A Common Stock
Cintas Analyst Upgrade	Todd M. Schneider	Director, CEO and Director	Grant, award, or other acquisition of securities at price $ 759.63 per share.	12 Aug 2024	18,119	165,055 (0%)	0%	759.6	13,763,736	Common Stock
Elutia Inc (Class A)	Matthew B. Ferguson	CHIEF FINANCIAL OFFICER	Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.84 per share.	12 Aug 2024	17,840	289,983	-	2.8	50,666	Class A Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner	Sale of securities on an exchange or to another person at price $ 9.00 per share.	12 Aug 2024	17,361	980,433	-	9	156,249	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner	Sale of securities on an exchange or to another person at price $ 9.00 per share.	12 Aug 2024	17,361	980,433	-	9	156,249	Common Stock
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner	Sale of securities on an exchange or to another person at price $ 8.00 per share.	12 Aug 2024	17,361	980,433	-	8	138,888	Common Stock
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner		12 Aug 2024	17,361	980,433	-	8	138,888	Common Stock
Amphastar Pharma Inc	Richard Prins	Director	Sale of securities on an exchange or to another person at price $ 43.07 per share.	12 Aug 2024	17,101	33,971 (0%)	0%	43.1	736,550	Common Stock
FTC Solar Inc High Loss High Volume	Pablo Barahona	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	16,960	20,960	-		0	Common Stock
Veracyte Inc	Evan Jones	Director	Sale of securities on an exchange or to another person at price $ 32.36 per share.	12 Aug 2024	16,838	35,031 (0%)	0%	32.4	544,851	Common Stock
Lamb Weston Results Board Meeting	Sylvia Wilks	Chief Supply Chain Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	16,463	16,463 (0%)	0%		0	Common Stock
Netflix Estimates Miss High Loss High Volume	Jay C. Hoag	Director	Sale of securities on an exchange or to another person at price $ 633.25 per share.	12 Aug 2024	16,336	349,519 (0%)	0%	633.3	10,344,803	Common Stock
Wave Life Sciences Ltd	Christian O. Henry	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	16,115	16,115 (0%)	0%		0	Ordinary Shares
Wave Life Sciences Ltd	Adrian Rawcliffe	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	16,115	16,115 (0%)	0%		0	Ordinary Shares
Wave Life Sciences Ltd	Gregory L. Verdine	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	16,115	46,115 (0%)	0%		0	Ordinary Shares
Wave Life Sciences Ltd	Ken Takanashi	Director, Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	16,115	5,721,175 (16%)	0%		0	Ordinary Shares
Wave Life Sciences Ltd	Aik Na Tan	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	16,115	16,115 (0%)	0%		0	Ordinary Shares
Aldeyra Therapeutics Inc	Stephen G. Machatha	Chief Development Officer		12 Aug 2024	16,041	236,771 (0%)	0%	4.7	75,975	Common Stock
Elutia Inc (Class A)	Michelle Leroux Williams	CHIEF SCIENTIFIC OFFICER	Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.84 per share.	12 Aug 2024	15,800	51,300	-	2.8	44,872	Class A Common Stock
Geovax Labs Inc	Mark W. Reynolds	CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	15,700	15,700	-		-	Stock Option
Geovax Labs Inc	Mark J. Newman	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	15,700	15,700	-		-	Stock Option
Geovax Labs Inc	Kelly T. McKee	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	15,700	15,700	-		-	Stock Option
a.k.a. Brands Holding Corp	Kenneth C. White	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	15,625	37,687	-		0	Common Stock, $0.001 par value per share
Applovin Corp (Class A)	Katie Jansen	Chief Marketing Officer	Sale of securities on an exchange or to another person at price $ 84.58 per share.	12 Aug 2024	15,046	1,094,557	-	84.6	1,272,591	Class A Common Stock
Cigna Group	Nicole S. Jones	See Remarks	Exercise or conversion of derivative security received from the company (such as an option) at price $ 149.13 per share.	12 Aug 2024	15,030	46,617 (0%)	0%	149.1	2,241,499	Common Stock, $.01 Par Value
Cigna Group	Nicole S. Jones	See Remarks	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	15,030	2,636	-		-	Employee Stock Option (Right to Buy)
CoreCivic Inc	Patrick Swindle	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 12.40 per share.	12 Aug 2024	15,000	203,504 (0%)	0%	12.4	186,000	Common Stock
Actuate Therapeutics Inc	Dan Zabrowski	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	15,000	15,000	-		-	Non-Qualified Stock Options
Actuate Therapeutics Inc	Aaron G.L. Fletcher	Director, Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	15,000	15,000	-		-	Stock Options
Actuate Therapeutics Inc	Leslie W. Kreis	Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	15,000	15,000	-		-	Stock Options
Actuate Therapeutics Inc	Todd S. Thomson	Director, 16.4% Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	15,000	15,000	-		-	Non-Qualified Stock Options
Aris Water Soln Inc (Class A)	D Dylan Van Brunt	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 14.84 per share.	12 Aug 2024	14,813	94,690	-	14.8	219,825	Class A Common Stock
Eli Lilly Acquisition	Anat Hakim	EVP, GC & Secretary	Gift of securities by or to the insider at price $ 0.00 per share.	12 Aug 2024	14,700	15,779 (0%)	0%		0	Common Stock
Hippo Holdings Inc	Yuval Harry	Chief Revenue Officer	Sale of securities on an exchange or to another person at price $ 18.52 per share.	12 Aug 2024	14,548	107,205	-	18.5	269,477	Common Stock
SiTime Corp	Lionel Bonnot	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	14,450	95,256 (0%)	0%		0	Common Stock
SiTime Corp	Piyush B. Sevalia	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	14,450	95,669 (0%)	0%		0	Common Stock
SiTime Corp	Fariborz Assaderaghi	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2024	14,450	117,553 (0%)	0%		0	Common Stock
CompoSecure Inc (Class A)	Amanda Gourbault	Chief Revenue Officer		12 Aug 2024	14,397	0	-	11.0	158,079	Class A Common Stock
Applovin Corp (Class A)	Katie Jansen	Chief Marketing Officer	Sale of securities on an exchange or to another person at price $ 74.66 per share.	12 Aug 2024	14,359	1,222,344	-	74.7	1,072,043	Class A Common Stock
Netflix Estimates Miss High Loss High Volume	Jay C. Hoag	Director	Sale of securities on an exchange or to another person at price $ 632.28 per share.	12 Aug 2024	14,315	129,875 (0%)	0%	632.3	9,051,072	Common Stock
Alnylam Pharma Inc	Kevin Joseph Fitzgerald	CSO & EVP, Head of Research	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2024	14,058	2,192	-		-	Stock Option (right to buy)
Alnylam Pharma Inc	Kevin Joseph Fitzgerald	CSO & EVP, Head of Research	Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.00 per share.	12 Aug 2024	14,058	34,906 (0%)	0%	85	1,194,930	Common Stock
Cardlytics Inc	John L. Klinck	Director	Purchase of securities on an exchange or from another person at price $ 3.49 per share.	12 Aug 2024	14,000	67,593 (0%)	0%	3.5	48,860	Common Stock
Spire Global Inc (Class A)	Leonardo Basola	Chief Financial Officer	Sale of securities on an exchange or to another person at price $ 7.10 per share.	12 Aug 2024	13,993	249,757	-	7.1	99,320	Class A Common Stock
Applovin Corp (Class A)	Katie Jansen	Chief Marketing Officer	Sale of securities on an exchange or to another person at price $ 76.50 per share.	12 Aug 2024	13,708	1,166,296	-	76.5	1,048,662	Class A Common Stock
Datadog Inc (Class A)	Alexis Le-Quoc	Director, Chief Technology Officer	Sale of securities on an exchange or to another person at price $ 110.91 per share.	12 Aug 2024	13,662	461,127 (0%)	0%	110.9	1,515,239	Class A Common Stock
Blue Bird Corp	Gurminder S. Bedi	Director	Sale of securities on an exchange or to another person at price $ 48.48 per share.	12 Aug 2024	13,256	5,640 (0%)	0%	48.5	642,651	Common Stock, par value $0.0001 per share

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.

Insider trading for US stocks based on disclosures made made on Aug 12, 2024

Monitor US insider transactions and discover insider buying and selling of stocks on Aug 12, 2024.

The latest disclosure under SEC insider trading regulations was reported by Citius Oncology Inc.., where the revocation of 3,700,000 Stock Option (Right to Buy) of common stock was executed . This transaction was reported to the Securities and Exchange Commission on Aug. 12, 2024.

Screeners based on Insider Trading parameters